2,000
Participants
Start Date
January 1, 2002
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
Radiotherapy
50-66Gy/1.8-2.2Gy/25-30f
Platinum based chemotherapy
q1-3W according to physician's preference
Paclitaxel based chemotherapy
q1-3W according to physician's preference
Immunotherapy
Anti-PD-1/PD-L1 Antibody
5-FU Analog based chemotherapy
W1-5 qW or d1-14, q3W according to physician's preference
Nimotuzumab
200-400mg, d1,qW
RECRUITING
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing
RECRUITING
Department of Radiation oncology, Jiangsu Cancer Hospital/Jiangsu Institute of Cancer Research/The affiliated Cancer Hospital of Nanjing Medical University, Nanjing
RECRUITING
Department of Radiation oncology, Jiangsu Province Hospital/The First Affiliated Hospital with Nanjing Medical University, Nanjing
RECRUITING
Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha
RECRUITING
Department 4th of Radiation Oncology, Anyang Cancer Hospital, Anyang
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OTHER